SecBot SecBot
PRESS-RELEASE ·Filed May 5, 2026

RGEN

Repligen Corporation
BULLISH
Impact 7/10
Horizondays Processed6mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ▲ Bullish

The strong beat and raised EPS guidance, combined with margin expansion and strategic divestiture, support a bullish read-through for RGEN. Monitor upcoming quarterly results for continued organic growth trajectory and Transformation Office execution, the reiterated 9%-13% organic revenue guide provides a clear benchmark.

DirectionBullish
Confidencehigh
Horizondays

Price Chart

Loading chart...

Executive Summary

Repligen reported Q1 2026 adjusted EPS of $0.48, beating the $0.38 consensus by 26.3%, and revenue of $194M (+15% YoY, +11% organic) above the $192.2M estimate. The company raised its full-year adjusted EPS guidance to $1.97-$2.05 (from prior $1.92-$2.00) while reiterating 9%-13% organic revenue growth, signaling confidence in margin expansion and operational execution.

Key Financial Metrics

EPS
$0.48
est $0.38 · +26.3%
Revenue
$194.0M
est $192.2M · +0.9% · +15.0% YoY
Rating
strong beat
Guidance
$803M-$833M
raised
Free Cash Flow
$23.6M
Gross Margin
55.7%

Key Facts

  • Q1 2026 adjusted EPS $0.48 vs consensus $0.38 (+26.3% beat)
  • Q1 2026 revenue $194M vs consensus $192.2M (+15% reported, +11% organic YoY)
  • GAAP EPS $0.15 vs $0.10 YoY; adjusted EPS $0.48 vs $0.39 YoY (+23%)
  • Adjusted operating margin expanded 160bps to 15.4% (from 13.8% YoY)
  • Full-year 2026 adjusted EPS guidance raised to $1.97-$2.05 (from $1.92-$2.00)
  • Full-year 2026 revenue guidance reiterated at $803M-$833M (9%-13% organic growth)
  • Divested non-core Polymem business (2025 rev $7M, operating loss) to sharpen focus
  • Cash and marketable securities $785M; operating cash flow $28.3M in Q1

Financial Impact

EPS beat of $0.10 vs consensus (+26%) and revenue beat of ~$1.8M (+0.9%)

epsrevenueoperating marginguidance

Risk Factors

  • GAAP EPS of $0.15 remains low due to $13.8M loss on sale of Polymem and $9.8M intangible amortization
  • Organic growth guidance of 9%-13% implies deceleration from Q1's 11% organic pace
  • China partnership and tariff exposure add execution and geopolitical risk

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
83% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3287476

US Market Status

Market Closed · Opens Wed (11h 54m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 5, 2026